percutaneous vertebroplasty
Conditions
Interventions
High-concentration bupivacaine liposome group(HB Group):HB group: Ultrasound-guided bilateral thoracic/lumbar posterior nerve root block was performed. The medication used was 0.133% liposomal bupivac
low-concentration bupivacaine liposome group(LB Group):LB group: Under ultrasound guidance, bilateral thoracic/lumbar spinal nerve posterior branches were blocked. The medication used was 0.0665% lipo
hydrochloric acid ropivacaine group((LP Group)):LP group: Ultrasound-guided bilateral thoracic/lumbar spinal nerve posterior branches block was performed. The medication used was 20 mL of 0.25% lidoca
Sponsors
No. 1 Orthopedics Hospital of Chengdu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 60-100 years, American Society of Anesthesiologists (ASA) physical status classification II-IV, any gender; 2. Body mass index between 18 kg/m^2 and 30 kg/m^2; 3. Normal cognitive function at admission (Mini-Mental State Examination >= 28); 4. Fully informed about this trial, willing to participate in this clinical trial, and able to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled hypertension and diabetes (systolic BP >= 180 mmHg, and/or diastolic BP >= 110 mmHg, blood glucose >= 15.0 mmol/L); 2. Patients with multiple fractures, multi-segment compression fractures, or combined injuries to other thoracic or abdominal organs; 3. Patients with a history of mental disorders, abuse of psychiatric or anesthetic drugs, who cannot cooperate with bedside ultrasound-guided posterior branch nerve blocks; 4. Patients with infection at the puncture site or coagulation disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative VAS pain score;Opioid drug consumption during surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time of the first postoperative ambulation;Total hospitalization time;postoperative hospitalization time;total hospitalization cost;rate of remedial analgesia;incidence of adverse events; | — |
Countries
China
Contacts
Public ContactWenzhi Wu
No. 1 Orthopedics Hospital of Chengdu
Outcome results
None listed